In one of the most significant cannabis deals in European history, Canadian company Cronos Group has announced the acquisition of CanAdelaar, the largest cannabis producer operating within the Dutch wietexperiment. The deal, valued at €57.5 million upfront with additional performance-based earnouts, gives Cronos the number one market share in what is now Europe's largest legal adult-use cannabis market.
The acquisition marks a major milestone for the Dutch cannabis industry and signals growing international confidence in the future of the wietexperiment, the Netherlands' landmark pilot program for regulated cannabis production and sales.
What Is the Wietexperiment?
The wietexperiment, officially enacted in 2020, was designed to create a closed, fully regulated cannabis supply chain in the Netherlands. The program covers ten participating municipalities, including Tilburg, Breda, Arnhem, Nijmegen, Groningen, Zaanstad, Almere, Maastricht, Hellevoetsluis, and Voorne aan Zee. All 72 coffeeshops in these municipalities are now required to source their cannabis exclusively from one of ten licensed producers.
The experimental phase officially launched on April 7, 2025, and is scheduled to run for four years, with the Dutch government retaining the option to extend it by an additional 18 months. Under the program, the import and export of cannabis products is prohibited, as are sales between licensed producers and supply to coffeeshops outside the participating municipalities.
About CanAdelaar
CanAdelaar was founded in 2018 and received its license under the wietexperiment in 2023. The company is headquartered in Voorne aan Zee and operates a massive 540,000 square foot facility that combines greenhouse cultivation with processing, production, and packaging. It is the only industrial-scale greenhouse cultivator among the ten licensed producers, with the others operating smaller indoor grow facilities.
The numbers tell the story of a rapidly growing business. CanAdelaar produces approximately 20,000 kilograms of dried flower annually and supplies nearly all 72 coffeeshops in the wietexperiment. Revenue grew from $17.7 million in 2024 to $47.3 million in the twelve months ending September 2025, while EBITDA jumped from $8 million to $28.2 million over the same period. The company sells flower, pre-rolls, hash, and edibles under its brand CanAdelaar Original Grow, or C.O.G.
Why Cronos Is Buying In
Cronos Group, listed on both NASDAQ and the Toronto Stock Exchange, described the acquisition as both financially compelling and strategically important. Cronos CEO Mike Gorenstein said the Netherlands has a deep cannabis heritage and praised the wietexperiment as a responsible, well-functioning adult-use market. He called the deal an ideal fit for the company's borderless product strategy, which has already made Cronos a market leader in Israel and Canada.
The upfront consideration of €57.5 million represents approximately 1.4 times CanAdelaar's trailing twelve-month revenue and 2.4 times its EBITDA, a valuation that analysts consider attractive given the growth trajectory. Additional earnout payments will be based on CanAdelaar's performance in 2026 and 2027.
The Bigger Picture
What makes this deal particularly significant is the potential for market expansion. The wietexperiment currently covers just 72 of the 562 coffeeshops in the Netherlands, spread across only ten municipalities. Amsterdam, by far the largest coffeeshop market in the country, is not included. If the Dutch government decides to expand the program to additional municipalities or nationwide, the addressable market could grow dramatically.
The deal also reflects a broader trend of North American cannabis companies moving into Europe. With Canada's domestic market maturing and price competition intensifying, companies like Cronos are looking to European markets for growth. Germany's booming medical cannabis market and the Netherlands' wietexperiment are among the most attractive opportunities on the continent.
What It Means for Dutch Coffeeshops
For the coffeeshops in the wietexperiment, the acquisition means that their largest supplier is now backed by significant international capital and expertise. Cronos has indicated it plans to leverage its investments in genetics, research, and product development to bring new products to the Dutch market, including improved flower varieties and potentially new product categories that are allowed under the wietexperiment, such as edibles and vapes.
The deal is expected to close before the end of March 2026, subject to regulatory clearances in the Netherlands. For the Dutch cannabis market, and for Europe as a whole, it represents a clear signal that the era of regulated, professional cannabis commerce is accelerating.
Stay up to date with the latest cannabis news from the Netherlands and across Europe on cannabizzz.nl.
